Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187


Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial.

Malapelle U, Raez LE, Serrano MJ, Rolfo C; International Society of Liquid Biopsies (ISLB).

J Thorac Dis. 2018 Dec;10(12):6388-6391. doi: 10.21037/jtd.2018.11.22. No abstract available.


Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.

Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, García-Puche JL, Robles-Fernández I, Exposito J, Martorell-Marugan J, Carmona-Sáez P, Garrido-Navas MDC, Rolfo C, Ilyine H, Lorente JA, Legueren M, Serrano MJ.

Breast Cancer Res. 2019 Feb 6;21(1):21. doi: 10.1186/s13058-019-1109-0.


Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.


Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.

Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C.

Adv Exp Med Biol. 2018;995:65-95. doi: 10.1007/978-3-030-02505-2_3.


The value of immunotherapy in head and neck cancer.

Manca P, Raez LE, Salzberg M, Sanchez J, Hunis B, Rolfo C.

Expert Opin Biol Ther. 2019 Jan;19(1):35-43. doi: 10.1080/14712598.2019.1556637. Epub 2018 Dec 20.


Spontaneous coronary artery dissection treated with magnesium-made bioresorbable scaffold: 1-Year angiographic and optical coherence tomography follow-up.

Quadri G, Cerrato E, Rolfo C, Varbella F.

Catheter Cardiovasc Interv. 2019 Feb 15;93(3):E130-E133. doi: 10.1002/ccd.27971. Epub 2018 Nov 12.


Bacterial imbalance and gut pathologies: Association and contribution of E. coli in inflammatory bowel disease.

Khan S, Imran A, Malik A, Chaudhary AA, Rub A, Jan AT, Syed JB, Rolfo C.

Crit Rev Clin Lab Sci. 2019 Jan;56(1):1-17. doi: 10.1080/10408363.2018.1517144. Epub 2018 Oct 29.


Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.

Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.

Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15.


Acute and long-term outcomes after polytetrafluoroethylene or pericardium covered stenting for grade 3 coronary artery perforations: Insights from G3-CAP registry.

Pavani M, Cerrato E, Latib A, Ryan N, Calcagno S, Rolfo C, Ugo F, Ielasi A, Escaned J, Tespili M, Conrotto F, Mancone M, Colombo A, Varbella F.

Catheter Cardiovasc Interv. 2018 Dec 1;92(7):1247-1255. doi: 10.1002/ccd.27789. Epub 2018 Sep 23.


Challenges in Lung Cancer Screening in Latin America.

Raez LE, Nogueira A, Santos ES, Dos Santos RS, Franceschini J, Ron DA, Block M, Yamaguchi N, Rolfo C.

J Glob Oncol. 2018 Sep;(4):1-10. doi: 10.1200/JGO.17.00040.


Biomarkers of response to immune checkpoint blockade in cancer treatment.

Fujii T, Naing A, Rolfo C, Hajjar J.

Crit Rev Oncol Hematol. 2018 Oct;130:108-120. doi: 10.1016/j.critrevonc.2018.07.010. Epub 2018 Aug 3. Review.


A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting.

Sorber L, Zwaenepoel K, De Winne K, Van Casteren K, Augustus E, Jacobs J, Zhang XH, Galdermans D, De Droogh E, Lefebure A, Morel AM, Saenen E, Bustin F, Demedts I, Himpe U, Pieters T, Germonpré P, Derijcke S, Deschepper K, Van Meerbeeck JP, Rolfo C, Pauwels P.

Cancers (Basel). 2018 Aug 27;10(9). pii: E290. doi: 10.3390/cancers10090290.


Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.

Rolfo C, Manca P, Salgado R, Van Dam P, Dendooven A, Machado Coelho A, Ferri Gandia J, Rutten A, Lybaert W, Vermeij J, Gevaert T, Weyn C, Lefebure A, Metsu S, Van Laere S, Peeters M, Pauwels P.

ESMO Open. 2018 Jul 23;3(5):e000398. doi: 10.1136/esmoopen-2018-000398. eCollection 2018.


CSF-1 and Ang-2 serum levels - prognostic and diagnostic partners in non-small cell lung cancer.

Coelho AL, Gomes MP, Catarino RJ, Rolfo C, Medeiros RM, Araújo AM.

ESMO Open. 2018 Jul 25;3(5):e000349. doi: 10.1136/esmoopen-2018-000349. eCollection 2018.


Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays.

Rolfo C, Raez L, Cristofanilli M.

JAMA Oncol. 2018 Oct 1;4(10):1430. doi: 10.1001/jamaoncol.2018.2320. No abstract available.


Potential new biomarkers for squamous carcinoma of the uterine cervix.

van Dam PA, Rolfo C, Ruiz R, Pauwels P, Van Berckelaer C, Trinh XB, Ferri Gandia J, Bogers JP, Van Laere S.

ESMO Open. 2018 Jun 28;3(4):e000352. doi: 10.1136/esmoopen-2018-000352. eCollection 2018.


Ultrafiltration and size exclusion chromatography combined with asymmetrical-flow field-flow fractionation for the isolation and characterisation of extracellular vesicles from urine.

Oeyen E, Van Mol K, Baggerman G, Willems H, Boonen K, Rolfo C, Pauwels P, Jacobs A, Schildermans K, Cho WC, Mertens I.

J Extracell Vesicles. 2018 Jul 3;7(1):1490143. doi: 10.1080/20013078.2018.1490143. eCollection 2018.


Vaccine and immune cell therapy in non-small cell lung cancer.

Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C.

J Thorac Dis. 2018 May;10(Suppl 13):S1602-S1614. doi: 10.21037/jtd.2018.05.134. Review.


Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, Van den Bossche J, Hermans C, Rolfo C, Peeters M, De Wever O, Lardon F, Siozopoulou V, Smits E, Pauwels P.

Oncoimmunology. 2018 Mar 19;7(7):e1440167. doi: 10.1080/2162402X.2018.1440167. eCollection 2018.


Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.


Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report.

Sorber L, Zwaenepoel K, Wouters A, Janssens A, Hiddinga B, Van Meerbeeck J, Lardon F, Pauwels P, Rolfo C.

J Clin Pathol. 2018 Aug;71(8):754-756. doi: 10.1136/jclinpath-2018-205210. Epub 2018 May 31. No abstract available.


Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?

Passiglia F, Raez LE, Rolfo C.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1076-S1080. doi: 10.21037/jtd.2018.03.92. No abstract available.


Importance of Close Surveillance of Patients With Conservatively Managed Spontaneous Coronary Artery Dissection.

Quadri G, Cerrato E, Escaned J, Rolfo C, Tomassini F, Ferrari F, Mariani F, Varbella F.

JACC Cardiovasc Interv. 2018 Jun 11;11(11):e87-e89. doi: 10.1016/j.jcin.2018.03.020. Epub 2018 May 16. No abstract available.


ROS-1 Rearrangements in Circulating Tumor Cells.

Raez LE, Manca P, Rolfo C, Singh V.

J Thorac Oncol. 2018 May;13(5):e71-e72. doi: 10.1016/j.jtho.2017.11.127. No abstract available.


To Decipher the Mycoplasma hominis Proteins Targeting into the Endoplasmic Reticulum and Their Implications in Prostate Cancer Etiology Using Next-Generation Sequencing Data.

Zakariah M, Khan S, Chaudhary AA, Rolfo C, Ben Ismail MM, Alotaibi YA.

Molecules. 2018 Apr 24;23(5). pii: E994. doi: 10.3390/molecules23050994.


Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress.

Deben C, Deschoolmeester V, De Waele J, Jacobs J, Van den Bossche J, Wouters A, Peeters M, Rolfo C, Smits E, Lardon F, Pauwels P.

Cancers (Basel). 2018 Apr 21;10(4). pii: E126. doi: 10.3390/cancers10040126.


Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?

Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, Morante Z, Araujo JM, Gómez HL, Aguilar A, Bretel D, Flores CJ, Rolfo C.

ESMO Open. 2018 Apr 13;3(3):e000344. doi: 10.1136/esmoopen-2018-000344. eCollection 2018.


Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.

Bronte G, Bravaccini S, Bronte E, Burgio MA, Rolfo C, Delmonte A, Crinò L.

Biol Rev Camb Philos Soc. 2018 Nov;93(4):1735-1746. doi: 10.1111/brv.12416. Epub 2018 Apr 19.


The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.

Raez LE, Cardona AF, Santos ES, Catoe H, Rolfo C, Lopes G, Barrios C, Mas LA, Vallejos C, Zatarain-Barrón ZL, Caglevic C, Arrieta O.

Lung Cancer. 2018 May;119:7-13. doi: 10.1016/j.lungcan.2018.02.014. Epub 2018 Mar 2. Review.


Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.

Camilli M, Papadimitriou K, Nogueira A, Incorvaia L, Galvano A, D'Antonio F, Ferri J, Santini D, Silvestris N, Russo A, Peeters M, Rolfo C.

Expert Rev Gastroenterol Hepatol. 2018 May;12(5):471-478. doi: 10.1080/17474124.2018.1463157. Epub 2018 Apr 18. Review.


Combining top-ranked immunotherapeutics in lung cancer.

Rolfo C, Smits ELJ.

Lancet Oncol. 2018 May;19(5):592-594. doi: 10.1016/S1470-2045(18)30186-4. Epub 2018 Apr 5. No abstract available.


Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M.

Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8.


Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.

Cardama GA, Alonso DF, Gonzalez N, Maggio J, Gomez DE, Rolfo C, Menna PL.

Crit Rev Oncol Hematol. 2018 Apr;124:29-36. doi: 10.1016/j.critrevonc.2018.01.012. Epub 2018 Feb 4. Review.


Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis.

Passiglia F, Rizzo S, Rolfo C, Galvano A, Bronte E, Incorvaia L, Listi A, Barraco N, Castiglia M, Calo V, Bazan V, Russo A.

Curr Cancer Drug Targets. 2018;18(7):697-705. doi: 10.2174/1568009618666180308125110.


KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.

Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I.

Mol Cancer. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. Review.


Choice of vascular access in primary PCI.

Tomassini F, Tarantino F, Cerrato E, Quadri G, Rolfo C, Varbella F.

Minerva Cardioangiol. 2018 Aug;66(4):400-410. doi: 10.23736/S0026-4725.18.04629-7. Epub 2018 Feb 1. Review.


Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.

Passiglia F, Caglevic C, Giovannetti E, Pinto JA, Manca P, Taverna S, Listì A, Gil-Bazo I, Raez LE, Russo A, Rolfo C.

Semin Cancer Biol. 2018 Oct;52(Pt 2):259-268. doi: 10.1016/j.semcancer.2018.01.015. Epub 2018 Jan 31. Review.


Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression.

Pucci M, Reclusa Asiáin P, Duréndez Sáez E, Jantus-Lewintre E, Malarani M, Khan S, Fontana S, Naing A, Passiglia F, Raez LE, Rolfo C, Taverna S.

Target Oncol. 2018 Apr;13(2):175-187. doi: 10.1007/s11523-018-0551-8.


Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2018 Jan 23;15(3):150. doi: 10.1038/nrclinonc.2018.13. [Epub ahead of print]


A synthetic lethal bullet.

Rolfo C, Giovannetti E.

Nat Nanotechnol. 2018 Jan;13(1):6-7. doi: 10.1038/s41565-017-0038-2. No abstract available.


The role of Nuclear Factor-kappa B signaling in human cervical cancer.

Tilborghs S, Corthouts J, Verhoeven Y, Arias D, Rolfo C, Trinh XB, van Dam PA.

Crit Rev Oncol Hematol. 2017 Dec;120:141-150. doi: 10.1016/j.critrevonc.2017.11.001. Epub 2017 Nov 7. Review.


Exosomes as diagnostic and predictive biomarkers in lung cancer.

Reclusa P, Taverna S, Pucci M, Durendez E, Calabuig S, Manca P, Serrano MJ, Sober L, Pauwels P, Russo A, Rolfo C.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1373-S1382. doi: 10.21037/jtd.2017.10.67. Review.


Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region.

Rolfo C, Zielinski CC.

Ann Thorac Med. 2017 Oct-Dec;12(4):219-220. doi: 10.4103/atm.ATM_225_17. No abstract available.


Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C, Lardon F, Smits E, Pauwels P.

Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26.


New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.

Rolfo C, Raez L.

Lab Invest. 2017 Nov;97(11):1268-1270. doi: 10.1038/labinvest.2017.91.


Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Anticancer Res. 2017 Nov;37(11):6429-6436.


Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix.

van Dam PA, Rolfo C, Ruiz R.

Eur J Surg Oncol. 2017 Dec;43(12):2245-2247. doi: 10.1016/j.ejso.2017.09.018. Epub 2017 Sep 28. No abstract available.


MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients.

Deben C, Op de Beeck K, Van den Bossche J, Jacobs J, Lardon F, Wouters A, Peeters M, Van Camp G, Rolfo C, Deschoolmeester V, Pauwels P.

J Cancer. 2017 Jul 15;8(12):2154-2162. doi: 10.7150/jca.19254. eCollection 2017.


Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.

Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, Rolfo C, Adamo V.

Crit Rev Oncol Hematol. 2017 Sep;117:38-47. doi: 10.1016/j.critrevonc.2017.07.003. Epub 2017 Jul 5. Review.


Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A.

Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1.

Supplemental Content

Support Center